Abstract
Objectives
Intravitreal injection of steroids is a rapidly evolving treatment option for a variety of retinal pathologies. There is wide variation among ophthalmologists regarding dose of steroid and the technique of injection. Through this survey we aim to describe the current practice of injection of intravitreal steroid among ophthalmic consultants in the United Kingdom and review the literature.
Methods
A postal questionnaire was sent to all the 901 ophthalmic consultants in the United Kingdom. The questions covered frequency of intravitreal steroid injections, subspecialty interest, dosage and volume of steroid, patient preparation, surgeon preparation, and postoperative management.
Results
The response rate to the questionnaire was 63%. A total of 24.7% perform intravitreal steroid injections regularly with 90% of users performing five or fewer injections per month. In all, 94% use a dose of 4 mg. Among surgeons, 38% do not prescribe postoperative antibiotics or steroids and 59% check intraocular pressure either on the same or the next day.
Conclusion
The relatively short experience with this technique has not yet allowed a clear picture to emerge of indications, complications or best practice administration. Published descriptions of intravitreal steroid injection techniques vary widely and variations are not evidence based. Observed UK practice is diverse.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Jonas JB, Sofker A . Intraocular injection of crystalline cortisone as an adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425–427.
Aiello PL, Brucker JA, Chang S, Cunningham Jr ET, D' Amico DJ, Flynn Jr HW et al. Evolving guidelines for intravitreous injections. Retina 2004; S3–S19.
Jonas JB, Hayler JK, Panda- Jonas S . Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064–1067.
Jonas JB, Hayler JK, Sofker A, Panda-Jonas S . Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468–471.
Jonas JB, Hayler JK, Panda- Jonas S . Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graef Arch Clin Exp Ophthalmol 2001; 239: 464–465.
Greenberg PB, Marthidis A, Rogers AH, Duker JS, Reichel E . Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247–248.
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J . Intravitreal triamcinolone for uveitic cystoid macular oedema: an optical coherence tomography study. Ophthalmology 2001; 108: 765–772.
Danis RP, Thomas A, Ciulla TA, Pratt LM, Anilekar W . Intravitreal triamcinolone acetonide in exudative age related macular degeneration. Retina 2000; 20: 244–250.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920–927.
Jonas JB, Kreissig I, Sofker A, Degenring RF . Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 2003; 121 (1): 57–61.
Hida T, Chandler D, Arena JE, Marchemer R . Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101: 190–195.
Yeung CK, Chan KP, Chan CK, Pang CP, Lam DS . The cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004; 48 (3): 236–242.
Jonas JB, Degenring RF, Kreissig I . Intravitreal injection of triamcinolone for diffuse macular oedema – in reply. Arch Ophthalmol 2004; 122: 1086–1088.
Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG et al. Intravitreal injection of triamcinolone for diffuse macular oedema. Arch Ophthalmol 2004; 122: 1085–1086.
Young ML, Kaiser PK, Sears JE . Acute endophthalmitis following intravitreal triamcinolone acetonide injection (abstract). In: Program and Abstracts of the American Academy of Ophthalmology 2002 Meeting. Orlando, FL, October 20–23, 2002.
Sutter FK, Gilles MC . Psuedo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: 972–974.
Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA et al. Non- infectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279–1282.
Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23 (5): 686–691.
Jonas JB, Kreissig I, Degenring RF . Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003; 121: 1663–1664.
Moshfeghi AA, Scott IU, Flynn Jr HW, Puliafito CA . Psuedohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138 (3): 489–492.
Moshfegi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791–796.
Gragoudas ES, Adamis AP, Cunnigham Jr ET, Feinsod M, Guyer DR et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 30; 351 (27): 2805–2816.
Chen SDM, Mohammed Q, Bowling B, Patel CK . Vitreous wick syndrome—a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am J Ophthalmol 2004; 137 (6): 1159–1160.
Ibarra MS, Hermel M, Prenner JL, Hassan TS et al. Longer-term outcomes of transconjunctival sutureless 25-gauge vitrectomy. Am J Ophthalmol 2005; 139 (5): 831–836.
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of intravitreal injection of triamcinolone. Arch Ophthalmol 2004; 122: 336–340.
Wingate RJ, Beaumont PE . Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431–432.
Jonas JB, Kreissig I, Degenring RF . Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24–27.
Author information
Authors and Affiliations
Corresponding author
Additional information
Proprietary interests: None
Funding: None
Appendix A: Questionnaire
Appendix A: Questionnaire
National survey of intravitreal triamcinolone injection technique
Rights and permissions
About this article
Cite this article
Anijeet, D., Hanson, R., Bhagey, J. et al. National survey of the technique of intravitreal triamcinolone injection in the United Kingdom. Eye 21, 480–486 (2007). https://doi.org/10.1038/sj.eye.6702232
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702232
Keywords
This article is cited by
-
Which quadrant is less painful for intravitreal injection? A prospective study
Eye (2019)
-
Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review
International Journal of Retina and Vitreous (2015)
-
UK national survey of current practice and experience of intravitreal triamcinolone acetonide
Eye (2009)
-
Reply to Ozkiris et al
Eye (2007)
